Most Clicked StoriesMore >


Janssen licenses Novo Nordisk's autoimmune therapy

BIO SmartBrief | May 21, 2015

Janssen Biotech secured the exclusive worldwide rights to develop and market an autoimmune diseases program from Novo Nordisk. Financial terms of the agreement were not disclosed. PharmaTimes (U.K.) (05/20) Nasdaq.com (05/20)


Biosimilars may not repeat success of generic drugs

BIO SmartBrief | May 21, 2015

Study: Lack of companion diagnostics hampers precision medicine's growth

BIO SmartBrief | May 19, 2015

Completed Pfizer-Hospira merger expected by year's end

BIO SmartBrief | May 20, 2015

Anti-inflammatory drug from Pharmaxis acquired by Boehringer

BIO SmartBrief | May 19, 2015

BioNTech partners with Genmab on cancer immunotherapies

BIO SmartBrief | May 20, 2015

NantPharma buys Sorrento unit, Cynviloq for up to $1.3B

BIO SmartBrief | May 18, 2015

Pfenex is developing Lucentis biosimilar

BIO SmartBrief | May 21, 2015

Banning of biotech foods validates unfounded fears

BIO SmartBrief | May 18, 2015

Cortendo obtains rights to Antisense Therapeutics' acromegaly drug

BIO SmartBrief | May 18, 2015


Find BIO SmartBrief Issues by Date:



BIO News More >


BIO announces new member benefit -- Executive Liability Protection through Aon Risk Solutions

BIO SmartBrief | May 22, 2015

BIO International Convention -- Register Now

BIO SmartBrief | May 22, 2015

Savings on environmental waste disposal services

BIO SmartBrief | May 20, 2015

Are you looking for top biotech talent? Or looking for a biotech job?

BIO SmartBrief | May 19, 2015

BIO announces new member benefit -- Executive Liability Protection though Aon Risk Solutions

BIO SmartBrief | May 18, 2015




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more